Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Losartan for the Treatment of Pediatric NAFLD (STOP-NAFLD): A Phase 2, Randomized, Placebo-Controlled Clinical Trial

NCT03467217 is registered in ClinicalTrials.gov with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as lead sponsor.

NCT NCT03467217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03467217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Losartan for the Treatment of Pediatric NAFLD (STOP-NAFLD): A Phase 2, Randomized, Placebo-Controlled Clinical Trial
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase
Phase 2
Overall status
Terminated
Start date
October 2, 2018
Completion date
June 30, 2020
Enrollment
83 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

nafld - nonalcoholic fatty liver disease